Image via STAT News (Pharmalot)
Last updated
Teva Pharmaceuticals: Ma Activity
Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.
Source: STAT News (Pharmalot)
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
Market context: MitchelLake's Talent Market Index sits at 107.8 (Hot), up 2.4 on the prior month; Oceania hiring signal is running easing (-7.9pts).
Teva Pharmaceuticals: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 25 tracked companies; 0.1% of MitchelLake's Oceania signal flow.
MitchelLake in this thematic
More signals across Biotech & Pharma
Ma Activity · Oceania
UCB →UCB acquiring Neurona Therapeutics for $650M plus up to $500M in milestones to expand epilepsy portfolio
Partnership · Oceania
AusBiotech →AusBiotech announced a strategic partnership with Tenmile venture capital firm to strengthen ecosystem connections and help Australian health startups access both domestic and international capital. The partnership extends prior collaboration on the Early Stage Innovation Forum and creates additional opportunities for startups and scale-ups.
Ma Activity · Americas
Biogen →Biogen announced and closed acquisition of Apellis Pharmaceuticals (immunology and rare diseases) in May 2026, and has just announced a second acquisition of an undisclosed company for $1 billion.
Ma Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Product Launch · Americas
Bristol Myers Squibb →Bristol Myers Squibb announced FDA acceptance of its New Drug Application for mezigdomide, an oral CELMoD candidate for relapsed or refractory multiple myeloma combination therapy.
Intelligence powered by Autonodal ↗